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Obesity and osteoporosis are two alarming health disorders prominent among middle
and old age populations, and the numbers of those affected by these two disorders are
increasing. It is estimated that more than 600 million adults are obese and over 200
million people have osteoporosis worldwide. Interestingly, both of these abnormalities
share some common features including a genetic predisposition, and a common origin:
bone marrow mesenchymal stromal cells. Obesity is characterized by the expression
of leptin, adiponectin, interleukin 6 (IL-6), interleukin 10 (IL-10), monocyte chemotactic
protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), macrophage colony stimulating
factor (M-CSF), growth hormone (GH), parathyroid hormone (PTH), angiotensin II (Ang
II), 5-hydroxy-tryptamine (5-HT), Advance glycation end products (AGE), and myostatin,
which exert their effects by modulating the signaling pathways within bone and
muscle. Chemical messengers (e.g., TNF-α, IL-6, AGE, leptins) that are upregulated or
downregulated as a result of obesity have been shown to act as negative regulators
of osteoblasts, osteocytes and muscles, as well as positive regulators of osteoclasts.
These additive effects of obesity ultimately increase the risk for osteoporosis and muscle
atrophy. The aim of this review is to identify the potential cellular mechanisms through
which obesity may facilitate osteoporosis, muscle atrophy and bone fractures.
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INTRODUCTION
Obesity is a multifactorial physical abnormality that is increasing worldwide as a result of increased
consumption of high-calorie diets, reduced physical activity, genetic predisposition, and excess
intake of glucocorticoids (GCs) (Lee et al., 2014; Andrade et al., 2015; Karaderi et al., 2015).
Recently, a number of large-scale genome-wide association studies (GWAS) have revealed the
genetic architecture and biological mechanisms of obesity, and more than 250 genetic loci have
been identified for monogenic, syndromic, or common forms of obesity (Karaderi et al., 2015).
Despite considerable public health efforts to control obesity, the outbreak of obesity has increased
over the past three decades in the United States (US). Epidemiological data suggest that nearly 36%
of the US adult population is currently obese (Feresin et al., 2014). Obesity has been implicated as a
potential precursor of several types of abnormalities like Type 2 diabetes mellitus (T2DM), cancer,
hypertension, heart disease, osteoarthritis, cerebrovascular disease, gastrointestinal abnormalities,
pulmonary abnormalities, metabolic syndrome, and dyslipidemia (Segula, 2014).
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Osteoporosis is characterized by decreased bone strength
and an increased risk of fractures resulting from decreased
bone mass and abnormal bone quality (Jackuliak and Payer,
2014). Osteoporosis has become a significant health problem
as approximately 200 million people worldwide are estimated
to have osteoporosis (Roy, 2013). Decreased bone mineral
density (BMD) observed in osteoporosis is associated with
decaying of the microarchitecture of bone, specifically the
trabecular sites including vertebrae, ribs and hips as well as
the cortical sites (Roy, 2013; Feresin et al., 2014; Bala et al.,
2015). Osteoporosis is initially asymptomatic at onset and is not
typically diagnosed until a fracture occurs (Roy, 2013). Females
are more susceptible to osteoporosis than males, although
excessive use of glucocorticoids, alcoholism, cigarette smoking,
low calcium intake and hypogonadism are also potential risk
factors for the development of osteoporosis (Lampropoulos et al.,
2012; Roy, 2013).
The incidence of osteoporosis and bone fractures has recently
been shown to be more prevalent in obese individuals than
individuals within a normal weight range (Halade et al., 2010;
Paula and Rosen, 2010; Cao, 2011). The complete mechanism
of obesity-induced osteoporosis is currently unclear, but there
has been evidence that consumption of a high fat diet leading to
increased total body fat mass (BFM) results in decreased BMD
(Halade et al., 2010). There are several possible mechanisms
through which obesity engenders the risk of osteoporosis and
muscle atrophy (Figure 1). The purpose of this review is to
identify cellular mechanisms through which obesity may regulate
bone cells and myocytes.
REGULATORS OF BONE FORMATION AND
RESORPTION
Osteoblasts, osteoclasts, and osteocytes are the main cells of
bone (Crockett et al., 2011). Osteoblasts are non-proliferative
bone-building cells that originate from osteoblast progenitor
cells and aid in formation of the bone matrix by secreting
osteoid, a substance responsible for bone mineralization (Dallas
et al., 2013). A mature osteoblast is known as an osteocyte.
Osteocytes are unable to divide and no longer secrete matrix
components. Osteocytes are thought to remodel their perilacunar
space, coordinate the response to mechanical loading and
unloading and perform nutrient/waste exchange through blood
(Lampropoulos et al., 2012; Dallas et al., 2013). Osteoclasts
originate frommacrophage monocyte cell lineage and participate
in bone resorption, ultimately leading to decreased bone mass
(Crockett et al., 2011; Lampropoulos et al., 2012).
Among the three cell types of bone, osteoblasts play the
most important role in bone formation. Preosteoblasts express
receptors for different types of growth factors, proinflamatory
cytokines and hormones including bone morphogenetic protein
(BMP), Wnt, transforming growth factor-β (TGF-β), PTH, Il-
6, 5-HT, insulin/insulin like growth factor (I/IGF) and TNF
(Lampropoulos et al., 2012; Roy, 2013). Binding of these ligands
with their corresponding receptors induces the activation of
different types of transcription factors responsible for osteoblast
differentiation, maturation and survival (Lampropoulos et al.,
2012). Obesity-induced adipocyte differentiation and lipid
accumulation in the body has been shown to decrease the
differentiation of osteoblasts since adipocytes and osteoblasts are
both derived from the same mesenchymal stem cell precursors.
This decrease in osteoblasts leads to decreased bone formation
(Chen et al., 2010; Cao, 2011).
Obesity Aided Regulation of Osteoblasts
Obesity Leads to Decreased BMP Signaling
BMPs are pleiotropic cytokines belonging to the TGF-β
superfamily and are known as potent inducers of osteogenesis
due to their role in inducing collagen synthesis and inhibiting
collagenase-3 production (Sanchez et al., 2015). Sixteen types
of BMPs have been identified and among them BMP-2, 6,
and 9 may have the most significant roles in osteoblast
differentiation from mesenchymal stem cells, although most
BMPs are able to stimulate osteogenesis in mature osteoblasts
(Cheng et al., 2003; Chen G. et al., 2012; Sanchez et al.,
2015). It has also been found that BMP-2 and BMP-6 trigger
osteoblast formation and chondrocyte proliferation, BMP-4 takes
part in endochondral ossification, and BMP-7 induces calcium
mineralization that is required for osteoblast differentiation
(Chen G. et al., 2012; Zhang et al., 2013; Rasi et al., 2016).
Contrarily, BMP-3 has adverse effects on osteoblastogenesis
(Kokabu et al., 2012). BMP signaling has been identified as
the major effector in preosteoblasts because binding of BMP
with its receptor (BMPRs) activates target genes through SMAD
dependent pathways or SMAD independent pathways (Chen G.
et al., 2012) (Figure 2). It has recently been identified that BMP-
2 exerts its effects on osteoblasts by inducing the expression
of two potential osteoblastogenic factors, Phospholipase C
β1 (PLCβ1) and Leucine-Rich Repeat Containing G Protein-
Coupled Receptor 4 (LGR4) (Pawaputanon Na Mahasarakham
et al., 2015; Ramazzotti et al., 2016). The net effect of
activation of BMP signaling is to activate transcription factors
necessary for the induction of osteogenesis. Matrix Gla protein
(MGP), Noggin, Sclerostin (SOST), and Gremlin have been
identified as several extracellular, intracellular and transcriptional
BMP inhibitors that are upregulated in obesity and act as
negative regulators of BMP signaling pathways, ultimately
downregulating osteoblastogenesis (Lampropoulos et al., 2012;
Roy, 2013). An in vitro study has shown that the presence
of high-density lipoprotein (HDL) and low-density lipoprotein
(LDL) in the body are consistent with elevated circulating MGP
(Thomsen et al., 2010). Noggin is a glycosylated protein that is
not only well-known for its inhibitory effects on BMP signaling
pathways by sequestering the BMP ligand, but it also induces
adipogenesis of mesenchymal stem cells. The association of
obesity with increased Noggin levels in mesenchymal stem cells
was confirmed in a preclinical, immunocompetent mouse model
of spontaneous obesity and in human patients with elevated body
mass index (Sawant et al., 2012). A recent study showed that pre-
adipocytes are resistant to BMP4 due to increased SOST of the
BMP inhibitor Gremlin 1 (Gustafson et al., 2015). Since BMP
signaling is known to play an essential role in the formation of
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FIGURE 1 | Obesity aided regulation of different factors and their role in bone and muscle. The up arrow “ ” indicates upregulation and the down arrow “ ”
indicates downregulation and the “NS” stands for not studied.
bone, BMP inhibitors will ultimately lead to decreased bone mass
and increased risk of fractures.
Obesity Decreases Activin Signaling via Upregulation
of FSTL1
Activin A is a member of the TGF-β superfamily of proteins
and has been identified as a positive regulator of bone and
cartilage development (Djouad et al., 2010; Lotinun et al.,
2012). Knockdown of Activin A by small interfering RNA
(siRNA) decreases the rate of chondrogenesis and osteogenesis
from mesenchymal progenitor cells (Djouad et al., 2010).
Like other TGF-β superfamily members, Activin transduces
its signals through type I (ACVRIB, ACVRIC) and type II
(ACVRIIA, ACVRIIB) receptor serine/threonine kinases. The
binding of Activin to its receptor induces the recruitment and
phosphorylation of the receptor. The activated receptor then, in
turn phosphorylates SMAD2 and SMAD3 intracellular signaling
proteins (Figure 2). Inhibins, FSTL1 and several other proteins
have been recognized as antagonistic to Activin signaling due
to their ability to interfere with Activin signaling through a
variety of mechanisms (Lotinun et al., 2012). Adipose tissue of
obese ob/ob mice as well as serum of overweight/obese subjects
express significantly increased levels of FSTL1 (Fan et al., 2013).
As FSTL1 is a known inhibitor of Activin signaling, obesity-
induced increase in FSTL1 could decrease osteogenesis, leading
to weakened bones and susceptibility to fractures.
Obesity-Induced Increases in DKK1 and SOST Inhibit
Wnt Signaling
The Wnt family of highly conserved secreted glycoproteins
is rich in cysteine residues and controls not only the vital
developmental processes of cell fate and polarity but also some
cell maintenance processes. In humans, more than 19 Wnts,
10 FZD receptors, and 2 co-receptors (LRP-5, LRP-6) have
been identified so far (Tornero et al., 2015). Among several
Wnt signaling pathways, the Wnt/β-cat dependent (canonical)
pathway has been well-characterized (Kim J. H. et al., 2013).
Binding of canonical Wnts with FZD receptors and LRP-5 or
LRP-6 co-receptors promote the activation of disheveled (DVL),
which in turn blocks the function of GSK3β, and prevents the
degradation of β-cat as well as subsequent translocation of β-cat
in the nucleus to activate the TCF/LEF family of transcription
factor (Kim J. H. et al., 2013; Many and Brown, 2014) (Figure 2).
Binding of non-canonical Wnts with the FZD receptor may
trigger three different signaling cascades: (1) recruitment of VDL
with FZD, which forms a complex with DAAM1 in order to
activate the transcription factor nuclear factor of activated T-
cells, cytoplasmic 1 (NFATC1) through subsequent activation of
RHO and RHO associated protein kinase (ROCK); (2) VDL may
form a complex with Rac to activate JNK followed by RUNX2
activation; and (3) Wnt may activate G proteins followed by
the activation of phospholipase C, which catalyzes the hydrolysis
of phosphatidylinositol-4,5-bisphosphate (PIP2) to IP3 and 1,2-
diacylglycerol (DAG) in order to enhance the concentration of
intracellular calcium ion (Ca2+) (Baron and Kneissel, 2013).
The net effect of Wnt signaling is to inhibit the activation of
negative regulatory transcription factors to allow for osteogenesis
to proceed.
Obesity has been shown to increase levels of the Wnt
inhibitors SOST and DKK1 (Armamento et al., 2012; Gustafson
and Smith, 2012; Sheng et al., 2012). DKK1 plays a crucial role
in the decrease of bone mass in obese individuals as it inhibits
the Wnt signaling pathway by binding to the Kremen/LDL
receptor–related protein receptors and thereby decreases the rate
of osteoblast differentiation. In addition, DKK1 has been shown
to increase the number of cells able to undergo adipogenesis
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FIGURE 2 | Possible adverse effects of obesity on osteoblasts. (a) Anabolic pathways: Binding of BMP with BMPR induces SMAD dependent and SMAD
independent pathways and ultimately transcribes the genes required for osteoblast formation. In the case of SMAD dependent signaling, activation of SMAD1/5/8
recruits SMAD4 to form a SMADs complex, which in turn transcribes particular gene/genes. SMAD 1/5/8 also activates specific genes via Osterix (Osx) mediated
signaling. In case of SMAD independent signaling, activated BMPR induces the transcription factor runt-related transcription factor 2 (RUNX2) and activator protein 1
(AP1) to be activated through P38MAPK/JNK/ERK signaling pathway. Obesity inhibits BMP signaling by upregulating the expression of some BMP inhibitors like MGP,
Noggin, SOST, and Gremlin. TGF-β/Activin may activate several receptor subtypes including ACVRIIA, ACVRIIB, ACVRIB, and ACVRIC. Like BMP signaling, Activin
also signals through SMAD dependent and SMAD independent pathways, but the main difference is that Activin induces SMAD2/3 and then recruits SMAD4 to form
a SMADs complex. Obesity decreases Activin signaling via upregulating the expression of follistatin-like 1 (FSTL1), a potential inhibitor of Activin signaling. Binding of
canonical with Frizzled/Lipoprotein receptor-related proteins (FZD/LRPs) complex activates vessel dilator (VDL), which in turns prevents β-catenin (β-cat) degradation
as well as subsequent translocation of β-cat into the nucleus to activate T cell factor/lymphoid enhancer factor (TCF/LEF) by sequestering Glycogen synthase kinase 3
β (GSK3β). Binding of non-canonical Wnt with FZD triggers three different signaling pathways: (1) FZD recruits LRP and disheveled associated activator of
morphogenesis 1 (DAAM1) to form a complex, which in turns activates the gene via RHO/ROCK/NFATC1 signaling pathway; (2) VDL forms a complex with Rac to
activate RUNX2 via c-Jun NH2-terminal kinase (JNK) activation; and (3) Activated FZD induces the activation of G protein, which in turn activates Phospholipase C
(PLC) to generate inositol-1,4,5-trisphosphate (IP3) to increase the cytosolic Ca2+ concentration and these Ca2+ act as negative regulators of peroxisome proliferator
activated receptor γ (PPAR-γ). Obesity decreases Wnt signaling by upregulating the expression of Wnt inhibitors like SOST and Dickkopf Wnt Signaling Pathway
Inhibitor 1 (DKK1). Upon activation of IGF-1 receptor (IGF-1R) by I/IGF-1 transcribes the corresponding genes through PI3K/AKT signaling and MAPK signaling
pathways. Activated protein kinase B (AKT) also inhibits Forkhead box O1 (FOXO1) and GSK3β resulting in decreased expression of negative regulatory elements.
Obesity-induced insulin resistance (IR) decreases I/IGF signaling. (b) Catabolic pathways: Decreased level of 5-HT from the brain suppresses bone formation by
facilitating the activation of β2 adrenergic receptor (Adrβ2), which transcribes Cyclin D1 (CycD1) inhibitory factor through PKA/ATF4 signaling pathway.
(Continued)
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FIGURE 2 | Continued
Adrβ2 also upregulates the expression of receptor activator of nuclear factor kappa-β ligand (RANKL) through an unknown pathway. Obesity is inversely related to
brain 5-HT2CR expression. PTH signaling has both positive and negative impacts on osteoblast development. Activated parathyroid hormone 1 receptor (PTH1R)
induces the activation of G protein, which in turn activates positive regulatory elements via cAMP/PKA/CREB signaling pathway although cAMP response element
binding protein (CREB) requires the recruitment of FOXO1 to be activated. PTH1R also inhibits Activin/TGF-β signaling by inhibiting the Activin receptor (ACVR).
Obesity causes the elevation of PTH via decreasing vitamin D synthesis. Duodenal 5-HT decreases PTH signaling by inhibiting protein kinase A (PKA) as well as
preventing the recruitment of FOXO1 with CREB resulting in decreased osteoblastogenesis. Obesity upregulates duodenal 5-HT expression. GC binds with the
glucocorticoid receptor (GR) to form the GC-GR activation complex, which induces osteoblast apoptosis through GSK3β/P38 signaling, generation of reactive oxygen
species (ROS) by endoplasmic reticulum (ER) stress and via activation of caspase 3/9 (Csp3/9). In addition, GSK3β inhibits β-cat activity and ROS inhibits Nuclear
factor-like 2 (Nrf2), a positive regulator of osteoblast. Sometimes GC activates the positive regulatory elements too. Excess GC uptake is associated with obesity. IL-6
induced JAK/STAT3 signaling has both positive and negative effects on osteoblast. In addition, IL-6 exerts its negative role via SHP2/PI3K/AKT signaling and via
SHP2/MEK2/ERK signaling pathways. Obesity induces IL-6 upregulation through increased generation of Ang II, AGE and leptin. TNF-α activated TNF receptor
(TNFR) activates nuclear factor-κB (NF-κB), which has both negative and positive roles in osteoblastogenesis. Obesity is responsible for increased synthesis of TNF-α.
by 3- to 4-fold, and this idea suggests that there may be a
proportional relationship between obesity and DKK1 (Gustafson
and Smith, 2012). Another potent inhibitor of Wnt signaling
is SOST, which positively correlates with fat mass of obese
individuals (Armamento et al., 2012; Sheng et al., 2012). SOST
and DKK1, through their inhibition of Wnt signaling, lead to
increased activation of transcription factors that act as negative
regulators of osteogenesis, leading to decreased bone formation.
Obesity-Induced Insulin-Resistance Leads to
Decreased I/IGF, PI3K/AKT, and MAPK Signaling
I/IGF and its downstream signaling pathways are indispensable
for osteoblast development during postnatal bone growth and
turnover (Pramojanee et al., 2014). The signaling pathway
through which IGF exerts its effect on osteoblast is well-
established. Several in vivo and in vitro studies have proposed
that treatment of osteoblasts with insulin induces the activation
of two signaling pathways: (1) PI3K/AKT signaling cascade
via the phosphorylation of IR/IGF-1R and its downstream
mediators, including insulin receptor substrate 1 (IRS-1), AKT,
GSK3β, FOXO1 and p70S6K, and (2) MAPK signaling via the
activation of Growth factor receptor-bound protein 2 (Grb2)
(Figure 2). Activation of PI3K/AKT signaling induces osteoblast
growth via upregulation of mammalian target of rapamycin
C1 (mTORC1) expression, glucose uptake via upregulation of
Glucose transporter type 4 (GLUT4) translocation and cell
survival via downregulation of FOXO1, proapoptotic proteins
like Bcl-2-associated death promoter (BAD), Bcl-2-like protein
11 (BIM) and caspases (Guntur and Rosen, 2013; Pramojanee
et al., 2014). Similarly, activation of MAPK signaling induces cell
proliferation via upregulation of RUNX2, Osterix and Cyc D1
and downregulation of p21cip and p27kip expression (Tahimic
et al., 2013; Pramojanee et al., 2014). High fat diet induced obesity
is positively correlated with IR in osteoblast and inversely related
to circulating osteocalcin (OC) levels (Reinehr and Roth, 2010;
Chahla et al., 2015) leading to decreased osteoblast proliferation.
Glucocorticoid Levels Seen in Obesity Inhibit
Osteoblast Proliferation
Chronic or long-term exposure to GCs, as seen in obesity,
inhibits osteoblast proliferation and reduces the availability of
preosteoblasts by shifting the differentiation of bone marrow
stromal cells (BMSCs) to favor adipocyte over osteoblast
differentiation through the upregulation of adipocyte regulator
CCAAT/enhancer-binding protein α (C/EBPα) (Li et al., 2013).
GCs have been reported to regulate the cell cycle by decreasing
the expression of Cyclin D3 (Cyc D3), the cyclic-dependent
kinases (CDKs) including CDK4 and CDK6, and by increasing
the transcription of CDK inhibitors such asp27 and p21 in
osteosarcoma cells. GR can reduce osteoblast proliferation by
suppressing CycD1 expression by binding with β-cat and by
dephosphorylating extracellular signal regulated kinase (ERK)
(Moutsatsou et al., 2012). GCs have also been reported to
inhibit osteoblastogenesis by inhibiting RUNX2, an important
osteogenic transcription factor (Rauch et al., 2010). Furthermore,
GC-GR complexes also suppress the expression of OC and
collagen type I through binding with negative Glucocorticoid
response elements (GREs) on the OC gene promoter (Rauch
et al., 2010; Li et al., 2013) and inhibit Wnt signaling by
preventing translocation of β-cat into the nucleus. GC-GR
complexes also induce apoptosis of osteoblasts by modulating
the expression of proapoptotic and antiapoptotic genes through
three different pathways: (1) GSK3β/P38MAPK pathway, (2)
mitochondria induced Csp3/Csp9 pathway, and (3) endoplasmic
reticulum (ER) stress induced ROS signaling pathways (Yun
et al., 2009; Lin et al., 2014; Sato et al., 2014) (Figure 2). It is well-
established that chronic use of steroid hormones, such as GCs,
trigger the development of obesity accompanied by rapid bone
loss (Ferris and Kahn, 2012; Lee et al., 2014).
Altered Serotonin Levels Seen in Obesity Lead to
Decreased Bone Formation
Serotonin or 5-HT is a monoamine neurotransmitter synthesized
in neurons of the brainstem and in enterochromaffin cells of the
duodenum (Oury et al., 2010). Osteoblasts have been reported
to express 5-HT1AR, 5-HT2AR, 5-HT1BR, 5-HT2BR, 5-HT2CR
and 5-HT1DR (Ducy and Karsenty, 2010; Vernejoul et al., 2012;
Dai et al., 2014) but among these subtypes, 5-HT2A and 5-HT1B
receptors have the highest expression levels at both early and late
stages of osteoblast differentiation (Dai et al., 2014). Bone mass is
critically regulated by 5-HT, which exerts its functions depending
on its site of synthesis (Ducy and Karsenty, 2010). Brain-derived
5-HT promotes three homeostatic functions: bone remodeling,
energy expenditure and appetite, whereas duodenal-derived 5-
HT inhibits osteoblast proliferation (Oury et al., 2010; Crane
et al., 2015). In the brain, 5-HT binds to 5-HT2CR in neurons
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of the ventromedial hypothalamic (VMH) nuclei and inhibits
the synthesis of epinephrine, thereby decreasing sympathetic
tone (Oury et al., 2010) (Figure 2). This decreased sympathetic
tone then, in turn, reduces the activity of β2 adrenergic
receptor (β2AR), which positively regulates osteoblastogenesis
via increased expression of CycD1 and decreased expression of
RANKL through the PKA/ATF4-dependent pathway (Ducy and
Karsenty, 2010). On the other hand, binding of gut-derived 5-
HT to 5-HT1BR present on osteoblasts inhibits cAMP production
as well as the phosphorylation of CREB and ultimately inhibits
osteoblast proliferation (Ducy and Karsenty, 2010; Oury et al.,
2010) (Figure 2). In 2012, Kode et al. proposed that the
transcription factor FOXO1 is a crucial determinant of duodenal
serotonin action in osteoblasts. They found that during normal
levels of circulating serotonin, the proliferative activity of FOXO1
in osteoblast is controlled by a balance between its interaction
with CREB and Activating transcription factor 4 (ATF4), but
elevated levels of circulating serotonin prevent the interaction of
FOXO1 with CREB and ultimately decrease the proliferation of
osteoblasts (Kode et al., 2012). Obesity is associated with elevated
peripheral serotonin and decreased levels of brain serotonin
(KimM. et al., 2013; Crane et al., 2015) and, thus, decreases bone
formation by both serotonin-dependent mechanisms.
IL-6 Is Increased in Obesity and Antagonizes
Osteoblast Differentiation
Overexpression of the IL-6 and IL-6 receptor (IL-6R) have been
documented as antagonistic to osteoblast differentiation since
IL-6 signaling strongly interferes with alkaline phosphatase
(ALP) activity, which downregulates the expression of
osteoblastic genes including RUNX2, Osterix, and OC, and
reduces the rate of mineralization (Kaneshiro et al., 2014).
Activation of IL-6R by binding of the extracellular IL-6 ligand
may trigger three different signaling pathways: SHP2/MEK/ERK,
SHP2/PI3K/AKT2, and JAK/STAT3 (Figure 2). The first two
signaling pathways downregulate osteoblastogenesis, but the
JAK/STAT3 signaling pathway acts both as a negative and
positive regulator of osteoblast differentiation, leading to a net
effect of decreased osteoblastogenesis. In the case of negative
regulation, signal transducers and activators of transcription 3
(STAT3) inhibits MAPK signaling, while in the case of positive
regulation, STAT3 acts as an osteogenic transcription factor
(Kaneshiro et al., 2014; Osta et al., 2014). A recent study revealed
that elevated IL-6 levels and increased expression of its soluble
receptor (IL-6R) correlated positively with body mass index
(BMI) and percent body fat. This finding suggests the role of
obesity as a positive modulator of IL-6R and IL-6 expression in
adipose tissue (Sindhu et al., 2015).
TNF-α Is Increased during Obesity and Inhibits
Osteoblast Differentiation
TNF-α is another factor that has been known as an inhibitor of
osteoblast differentiation and an activator of osteoclastogenesis
(Osta et al., 2014). TNF-α treated pre-osteoblast (MC3T3-E1)
cells show increased expression of cAMP response element-
binding protein H (CREBH) by upregulating the NF-κB signaling
pathway, and thereby inhibit BMP2 induced production of
RUNX2, ALP, and OC (Figure 2). It has also been revealed
that CREBH induces the expression of SMAD ubiquitination
regulatory factor 1 (Smurf1), which in turn degrades SMAD1
via ubiquitination (Jang et al., 2015). Another study proposed
that TNF-α not only induces the ubiquitination of SMADs
through activating Smurf1 and Smurf2, but also upregulates
DKK1 and SOST, which are potential inhibitors of BMP and
Wnt signaling. Due to these effects on signaling, elevated levels of
TNF-α are associated with osteoblast apoptosis (Bin et al., 2015).
Decreased levels of TNF-α can favor osteogenic differentiation
by upregulating the expression of BMP-2, Osx, RUNX2 and OC
through a NF-κB mediated signaling pathway (Osta et al., 2014).
A recent study showed that obesity mainly exerts its inhibitory
effect on osteoblastogenesis by TNF-α, secreted from adipocytes
(Abuna et al., 2016).
Obesity-Induced Decrease in Estrogen Production
Decreases Osteoblast Development
Reduced estrogen levels negatively regulate osteoblast
development, but the exact mechanism is still unknown. A
recent study demonstrated that estrogen signaling in osteoblasts
indirectly downregulates SOST expression through interaction
with BMP2-SMAD signaling pathway (Kim et al., 2015).
Almeida et al. have demonstrated that estrogen receptor-α (ERα)
expressed on osteoblast progenitor cells induce the expression
of Osterix1 (Osx1), which potentiated Wnt/β-cat signaling,
and thereby increased the proliferation and differentiation of
periosteal cells (Almeida et al., 2013). It has been shown that
obesity is negatively correlated with serum estradiol levels in
females (Freeman et al., 2010).
Reduced EPCs and Increased AGEs Observed in
Obesity Decrease Bone Strength and Healing
Endothelial progenitor cells (EPCs) are bone marrow-derived
stem cells, which have been recognized as angiogenic factors
during bone healing (Keramaris et al., 2012; Sun et al.,
2014). Obesity is associated with reduced expression of EPCs
through different mechanisms and thereby decreases the rate of
angiogenesis required for bone formation in the fracture sites
(Chen Y. L. et al., 2012; Sun et al., 2014). Mice fed a high fat
diet for 22 weeks expressed lower numbers of circulating as well
as differentiated EPCs compared to mice on a high fat diet for
14 weeks (Chen Y. L. et al., 2012). Thus, not only does obesity
increase the risk of fracture, but it also decreases the efficiency
of fracture healing. The numbers of advanced glycation end
products (AGEs) are inversely correlated with bone toughness
and rigidity, due to their role in the inhibition of the synthesis
of type I collagen, although the exact mechanism behind this
is still unknown (Roy, 2013; Yang et al., 2014). It is now well
researched that obesity is connected with increased amounts of
AGE in the body (Unoki et al., 2010; Andrade et al., 2015), leading
to decreased bone toughness.
Obesity Aided Regulation of Osteoclasts
Monocyte/macrophage cell lineage derived cells that are directly
involved in osteoclastogenesis are known as osteoclasts. It is
well characterized that different types of mediators such as
NF-κB, RANKL, osteopontin (OPN), TNF-α, IL-6, M-CSF, and
monocyte chemoattractant protein 1 (MCP1) have prominent
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roles to induce this process (Redlich and Smolen, 2012; Roy,
2013).
RANKL Mediates Bone Resorption
RANKL is the main driver of osteoclast mediated bone
resorption, and is secreted from osteoblasts and stromal cells. It
functions by binding receptors expressed on the surface of cells
of the monocyte/macrophage lineage and thereby induces the
differentiation of pre-osteoclasts to osteoclasts via the activation
of NF-κB and NFATC1 (Kim et al., 2010). RANKL inhibits
osteoclast apoptosis through upregulation and expression of
the antiapoptotic enzyme protein kinase B (PKB) (Figure 3)
(Roy, 2013). RANKL is also implicated as a potent inducer of
ROS, including free radicals, oxygen ions and peroxides, which
facilitate osteoclast differentiation (Lee and Jang, 2015).
Binding of RANKL with RANK activates adaptor protein
TRAF6 and subsequently activates several kinases including
MAPK, JNK, and ERK. These kinases, in turn, induce
FIGURE 3 | Possible adverse effects of obesity on osteoclast. Upon binding of RANKL with the receptor activator of nuclear factor kappa-β (RANK) activates
the adaptor protein TNF receptor-associated factor 6 (TRAF6), which thereby activates the transcription factor NFATC1 via three different signaling pathways: (1)
MAPK/AP1 mediated (2) IKK/NF-κB mediated, and (3) Rac/ROS/PLCγ/Ca2+/calcineurin mediated. Obesity induces RANKL signaling by decreasing the production of
osteoprotegerin (OPG), a RANKL antagonist. IL-6 induces IL6R activation and thereby positively regulates the osteoclastic gene by the JAK/STAT signaling pathway.
Binding of MCP1 with the C-C motif chemokine receptor 2 (CCR2) induces osteoclasogenesis via JAK/STAT and Ras/MAPK signaling pathways. TNF-α activates TNF
receptor 1 (TNFR1) and this activation leads to recruits TNFRSF1A associated via death domain (TRADD) and Receptor-Interacting Protein 1 (RIP1) with TNFR1 and
this complex thereby activates TRAF2/5/6, which in turn activates the specific gene via IKK/NF-κB and MAPK mediated signaling pathways. M-CSF activates NFATC1
through PI3K/AKT/NF-κB mediated signaling pathway or induces the activation of transcription factors peroxisome proliferator-activated receptor gamma (PPARγ)
and hypoxia-inducible factor 1-alpha (HIF1α) through the PI3/AKT/mTOR signaling pathway. Obesity is associated with increased expression of IL-6, TNF-α, MCP1,
and M-CSF.
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the activation of NFATC1 via the activation of various
hetero and homodimers of the AP1 family of proteins
(Redlich and Smolen, 2012) (Figure 3). Activated TRAF6 also
induces NFATC1 activation through two different signaling
pathways: (1) NF-κB mediated signaling pathway and (2)
Rac/ROS/PLCγ/Ca2+/calcineurin mediated signaling pathway
(Kikuta and Ishii, 2013; Moelants et al., 2013). NFATC1 regulates
the differentiation, proliferation, survival and apoptosis of
osteoclasts (Kikuta and Ishii, 2013). Obesity is associated with
increased production of RANKL by osteoblasts as well as elevated
levels of the RANKL/OPG ratio, where OPG is an antagonist of
RANKL activation (Xu et al., 2013).
In 2011, Hodge et al. found that M-CSF aids in RANKL
activation because incorporation of M-CSF with RANKL
accelerates the resorption processes more than with
RANKL alone (Hodge et al., 2011). M-CSF has been shown
to induce the activation of NFATC1 through PI3K/AKT/NF-
κB mediated signaling pathway or through the activation
of the transcription factors PPARγ and HIF1α through
PI3K/AKT/mTOR signaling pathway (Redlich and Smolen,
2012; Kikuta and Ishii, 2013) (Figure 3). NFATC1 is an
important transcription factor of osteoclastogenesis because,
together, with AP1 and NF-κB, it transcribes the genes which
encode the calcitonin receptor (CTR), tartrate-resistant acid
phosphatase (TRAP), matrix metalloproteinase 9 (MMP9),
matrix metalloproteinase 13 (MMP13), IL-6, IL-1, TNF,
cathepsin K (CTSK), and carbonic anhydrase II (CA2). These
proteins are required for the differentiation, proliferation, and
survival, of osteoclasts as well as for acidification and degradation
of bony matrix (Redlich and Smolen, 2012; Kikuta and Ishii,
2013; Moelants et al., 2013).
CTSK is a cysteine protease enzyme derived from bone
resorbing macrophages and synovial fibroblasts that plays an
important role in osteoclast function and in the degradation of
type I and type II collagen, osteonectin and elastin which are
essential bone components (Paula and Rosen, 2010). A study
conducted in a mouse model found that inhibition of CTSK
activity blocked the lipid accumulation in human and mouse
preadipocytes. Thus, it is plausible that the serum CTSK levels
are elevated in obese individuals (Yang et al., 2008), leading to
increases in osteoclast proliferation.
Other Regulators of Osteoclasts
Obesity is characterized by the expression of elevated levels
of proinflammatory cytokines and chemokines like TNF-α, IL-
1, IL-6, and MCP-1, and these factors have adverse effects on
the differentiation and activation of osteoblasts while having
supportive effects on osteoclasts (Weisberg et al., 2003; Cao,
2011; Redlich and Smolen, 2012; Makki et al., 2013). In
addition, obesity is associated with increased expression of
leptin with decreased expression of adiponectin (Makki et al.,
2013). Leptin activates β-2 adrenergic receptors on osteoblasts
through the sympathetic nervous system and thereby decreases
the differentiation and activation of osteoblasts while increasing
the activity of osteoclasts in bone resorption. Hence, increased
secretion of leptin is detrimental to bone formation while
supportive for bone resorption (Ng and Duque, 2010; He
et al., 2011). Adiponectin stimulates the differentiation and
mineralization of the osteoblast, but directly inhibits osteoclast
activity and bone resorption (Zhang et al., 2014). Ang II is
another factor that positively regulates osteoclast maturation and
activation. Recent studies have shown that plasma angiotensin
receptor type two (AT-II) concentration increases significantly
during obesity (Kotsis et al., 2010; Lampropoulos et al.,
2012). OPN is an integrin binding glyco-phosphoprotein that
binds with integrin receptors resulting in osteoclast activation
(Lampropoulos et al., 2012). Diet induced and genetically
obese mice are associated with 40- and 80-fold upregulation
of OPN, respectively (Kahles et al., 2014). PTH upregulates
osteoclast function, but downregulates osteoblast function and
thereby facilitates bone resorption (Lampropoulos et al., 2012).
A statistical analysis showed that elevated levels of PTH are more
prevalent in obese people than lean people (Valina et al., 2012).
ERα has been implicated as an inhibitor of osteoclast activity
because Almeida et al. have shown that expression of ERα in
osteoclasts prevents resorption of cancellous bone (Almeida et al.,
2013).
Obesity Aided Regulation of Osteocytes
Osteocytes are fully mature osteoblasts that are abundantly
(more than 90%) distributed throughout the mineralized bone
matrix and bone surface (Bellido, 2007). Osteocytes form the
lacunocanalicular network that acts as a mechanosensory system
and is appropriate for mechanotransduction through which
mechanical energy is transformed into biochemical signaling.
Osteocyte apoptosis is very important to osteoclastogenesis
because apoptotic osteocytes release immunostimulatory
molecules that instruct nearby osteocytes and macrophages to
produce VEGF, RANKL and other proinflamatory cytokines like
TNF-α, IL-6, IL-1 (Jilka et al., 2013; Komori, 2013). Physical
inactivity is a major cause of osteocyte apoptosis and it has
been observed that individuals with long lasting bed rest and
victims of paralysis have a greater chance of inducing osteocyte
apoptosis (Bellido, 2007). Obesity is directly associated with
physical immobilization (Pietilainen et al., 2008) and decreased
synthesis of estrogen in the body (Freeman et al., 2010). Elevated
GC levels and low-levels of estrogen are associated with higher
prevalence of osteocyte apoptosis (Moutsatsou et al., 2012; Jilka
et al., 2013). Reduced estrogen levels are also associated with
increased production of TNF-α, that is inhibiting NO production
and intracellular Ca2+ while strongly reducing F-actin content,
resulting in decreased osteocyte stiffness followed by loss of bone
mass (Osta et al., 2014). These additive effects increase osteocyte
apoptosis within obese individuals.
Obesity Aided Regulation of Bone
Microcirculation
Obesity induces adipocyte differentiation from mesenchymal
stem cells. The differentiated lipid cells accumulate within
the bone marrow, thereby expanding the area of marrow
cavity. The expanded bone marrow cavity containing bone is
more susceptible to fractures than bone without an expanded
cavity. The expanded bone cavity also leads to decreased bone
microcirculation (Cao, 2011). Type I collagen and minerals are
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two important structural components of the bone tissue and
the bone strength primarily depends on the quantity of collagen
and BMD. An in situ study by Chun et al. concluded that
high-fat diets acutely trigger the MMP14-dependent degradation
of type I collagen fibers (Chun et al., 2010). Other studies
have demonstrated a differential impact of lipid on BMD with
visceral adipose tissue (VAT) having potential detrimental effects
on BMD (Bredella et al., 2011). High fat diet (HFD) has a
pivotal role in bone formation because it markedly reduces the
rate of Ca2+ absorption by the intestine and thereby decreases
the availability of Ca2+ required for osteogenesis (Xiao et al.,
2010; Cao, 2011). Decreased levels of vitamin D are a hallmark
of osteoporosis and bone fractures (Roy, 2013). Vitamin D
deficiency in the serum prevents intestinal uptake of Ca2+ from
the diet and thereby signals the parathyroid gland to secret
increased levels of PTH. Increased secretion of PTH induces
osteolysis and prevents osteogenesis by supplying adequate levels
of calcium and phosphorus in the blood necessary for metabolic
processes and neuromuscular function (Stojanovic et al., 2011;
Binkley, 2012). Although a normal level of PTH is beneficial to
bone health, elevated secretion of PTH has been identified as
a negative regulator of osteoblastogenesis (Zhang et al., 2011;
Lampropoulos et al., 2012). During normal levels of PTH in the
blood, it binds the PTH1R and induces the expression of BMP2
via PTH1R-cAMP-PKA-CREB signaling pathway (Zhang et al.,
2011). In contrast, during hyper secretion of PTH, binding of
PTH with PTH1R activates PKA and ERK and then, in turn,
induction of the expression of MGP on the osteoblast, which
is a potent inhibitor of BMP signaling (Lampropoulos et al.,
2012; Roy, 2013). PTH binding also causes the internalization
of the PTH1R-TGFβR complex that sequesters TGF-β signaling
in osteoblastogenesis (Chen G. et al., 2012). Vitamin D is not
only playing a role in calcium and phosphorus homeostasis in the
blood, but it is also required for the activation of skeletal muscle
as muscle contraction is a calcium dependent process (Stojanovic
et al., 2011; Binkley, 2012; Girgis et al., 2013). Obesity is a
possible risk factor for decreases in vitamin D related functions
because vitamin D levels are significantly lower in obese subjects
compared to lean subjects and this results in an increased risk of
bone fracture and osteoporosis (Segula, 2014; Pereira et al., 2015).
Beyond the effect of HFD in bone formation, HFD is also
responsible for increased body weight. This excess body weight
may exert its pressure on the skeletal system as well as increase
the risk of falling and thereby induce the risk of fractures of the
weak bones (Townsend et al., 2008; Himes and Reynolds, 2012).
Several researchers have come to the conclusion that although
obesity may be helpful for bone health, obesity and DM induced
neuropathy may trigger osteolysis (Sinacore et al., 2008).
Systemic oxidative stress has been identified as a potential
risk factor of osteoporosis and bone fractures because increased
ROS due to lipid oxidation sequesters the differentiation of
preosteoblasts to osteoblasts through inhibiting Wnt signaling
while inducing RANKL mediated osteoclast activation (Ng and
Duque, 2010; Srinivasan et al., 2010). Oxidative stress also
triggers the overexpression of PPAR-γ and thereby induces the
differentiation of adipocytes, rather than osteoblasts, from MSC
(Ng and Duque, 2010). One study conducted on a mouse model
indicated thatmice deficient in superoxide dismutase (SOD) have
elevated oxidative stress and decreased muscle mass and strength
compared to wild-type mice (Smietana et al., 2010). Numerous
studies have come to the conclusion that obese individuals
contain high-levels of ROS in their adipose tissue due to over
nutrition and inflammation (Krawczyk et al., 2012).
EFFECT OF OBESITY ON MUSCLE
Muscle atrophy is a physiological condition that is associated
with decreased protein synthesis as well as accelerated
degradation of myofibrillar and soluble proteins (Roy, 2013).
Decreased protein synthesis leads to the rapid loss of skeletal
muscle mass followed by weakness of muscle resulting in the
increased risk of falling and ultimately bone fractures (Roy, 2013;
Cohen et al., 2015). Muscle atrophy targets skeletal muscles
due to denervation, fasting and various diseases like AIDS,
T2DM, obesity, sepsis, renal and cardiac failure, increased GCs,
trauma, and cancer. Degradation of muscle proteins takes place
through two different mechanisms: ubiquitin proteosome system
(UPS) and autophagy (Sala et al., 2014; Cohen et al., 2015).
Myofibrillar protein components are mainly degraded by UPS,
and when cellular organelles, such as mitochondria, undergo
autophagy. Degradation of muscle fibers is followed by reduction
of muscle strength and loss of mitochondria in myocytes due to
reduced energy resulting from the deficiency of ATP synthase
(Bonaldo and Sandri, 2013; Nassir and Ibdah, 2014). Muscle-
specific RING-finger 1 (MuRF1) and atrogin 1 are two major
ubiquitin ligases which are widely expressed in most types of
atrophy (Schiaffino and Mammucari, 2011; Polge et al., 2015).
MuRF1 has been identified as a potent regulator of important
muscle structural proteins, including myosin heavy and light
chains, troponin I, and myosin binding protein C (Bonaldo
and Sandri, 2013; Schiaffino et al., 2013). Atrogin-1 induces
degradation of MyoD and eukaryotic translation initiation
factor 3 subunit F (eIF3f), which are important for activation
of myogenic transcription factors and activation of protein
synthesis, respectively (De Larichaudy et al., 2012; Lokireddy
et al., 2012). Expression of both MuRF1 and atrogin-1 have
been shown to be elevated in obese mice muscle compared to
nonobese mice (Wang et al., 2010; Sishi et al., 2011). In addition
to Murf-1 and atrogin-1, muscle atrophy is also induced by
other factors including myostatin, FOXO, inducible nitric oxide
synthase (iNOS), and Csp3. It has been well-established that
obesity is associated with the upregulation of these factors in
muscle cells as well (Perreault and Marette, 2001; Cohen et al.,
2015).
Muscle growth is primarily regulated by two major signaling
pathways: (1) The IGF-1–PI3K–AKT/PKB–mTOR pathway that
induces protein synthesis and inhibits proteolysis and (2) The
myostatin–SMAD3 pathway which inhibits protein synthesis
and induces proteolysis (Egerman and Glass, 2014). Several
additional pathways have also been implicated in the regulation
of muscle growth. Leptin signaling has been shown to function as
a positive regulator of muscle protein synthesis, whereas RAGE-
MAPK, GC, Ang II, TNFR-P38/MAPK-NFκB, IL6-JAK-STAT
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signaling contribute negatively (De Larichaudy et al., 2012;
Munoz-Canoves et al., 2013; Patel et al., 2014; Pellegrinelli
et al., 2015). IL-10, adiponectin, and omentin have beneficial
roles in muscle hypertrophy, and interferon-γ (IFN-γ) negatively
regulates myogenesis, although the exact signaling pathways of
these molecules in muscle cells have not been identified to date
(Kim et al., 2004; Liu and Sweeney, 2014; Pelosi et al., 2014).
Effect of I/IGF-1 on Muscle
The exact role of I/IGF-1 in skeletal muscle has been extensively
examined, and it was discovered that I/IGF-1 is the major
protein synthesis pathway in skeletal muscle (O’Neill et al.,
2015; Sharples et al., 2015) In order to determine the effect of
I/IGF signaling on skeletal muscle mass, O’Neill et al. generated
mice with muscle-specific knockout of IGF-1R and the insulin
receptor (IR). The IGF-1R/IR knockout mice showed greater
than 60% decrease in muscle mass, confirming the vital role
of I/IGF signaling on skeletal muscle mass (O’Neill et al.,
2015). The role of IGF-1 signaling in muscle atrophy is mainly
determined by the activity of AKT, which is an intermediate
signaling molecule of the IGF-1 pathway. AKT induces activation
of the mammalian target of rapamycin (mTOR), which then
activates S6K1, ultimately stimulating protein synthesis (Hitachi
and Tsuchida, 2014) (Figure 4). AKT prevents proteolysis by
repressing the FOXO family of transcription factors, and induces
protein synthesis through the mTOR signaling pathway. GSK3β
is a potential inhibitor of protein synthesis due to its ability
to inhibit Eukaryotic translation initiation factor 2B (eIf2B)
and nebulin. AKT plays a major role in muscle growth by
sequestering GSK3β, thus preventing GSK3β’s inhibition of
protein synthesis (Schiaffino et al., 2013). It is well documented
that obesity, T2DM and metabolic syndrome are associated
with the progression and development of IR (Martins et al.,
2012; Ruiz-Alcaraz et al., 2013). Decreased mRNA levels of IRS-
1, phosphoinositide 3-kinase (PI3K), GLUT-1, GLUT-4, GSK-3
isoforms and phosphoinositide-dependent kinase-1 (PDK1) were
observed in an expression study conducted on muscle samples
of obese women (Colomiere et al., 2010). Similarly, reduced
activation of AKT, p70S6 kinase, and mTOR were found in
the skeletal muscle of obese mice and Zucker rats (Akhmedov
and Berdeaux, 2013). Phosphatase and tensin homolog deleted
on chromosome 10 (PTEN) is a lipid phosphatase that acts
against the action of PI3K by converting phosphatidylinositol
(3,4,5)-trisphosphate (PIP3) to PIP2 and preventing AKT from
docking on the plasma membrane (Schiaffino et al., 2013). It has
been demonstrated in mice fed a high fat diet, that PIP3 levels
are reduced, while PTEN expression was increased (Akhmedov
and Berdeaux, 2013). This observation supports the notion that
obesity-induced increases in PTEN directly decrease muscle
growth through the inhibition of AKT.
Effect of Myostatin on Muscle
Myostatin is known as a negative regulator of myogenesis
and is produced mainly by skeletal muscle, as shown by the
finding that myostatin induces FOXO dependent upregulation
of atrophy-related ubiquitin ligases like MuRF1 and atrogin 1
in cultured myocytes (Bonaldo and Sandri, 2013). Deactivation
of the IGF-1-PI3K-AKT signaling pathway and upregulation of
FOXO1 signaling is achieved by myostatin treatment (Rodriguez
et al., 2014). Several studies have reported that binding of
myostatin with its receptor, ActRIIB, activates SMAD 2/3
dependent signaling pathways in order to transcribe atrogenes
(MacKenzie et al., 2013) (Figure 4). The proteins generated
from these atrogenes inhibit the expression of MyoD and
myogenin. Increased phosphorylation of SMAD2/3 proteins
in obese individuals is associated with elevated levels of
myostatin in skeletal muscle as well as an approximately two-
fold decrease in MyoD and myogenin mRNA levels (Akhmedov
and Berdeaux, 2013). Research conducted on extremely obese
women determined the expression levels of myostatin within
their myotubes had a 2.9-fold increase in the secretion of
myostatin. From this data, it can be concluded that elevated levels
of myostatin are associated with obesity (Hittel et al., 2009), and
that this contributes to decreased muscle mass.
Effect of Leptin on Muscle
Leptin is a 167-amino acid peptide and is the product of the ob
gene that is secreted by white adipose tissue (WAT) and also by
a variety of other tissues including placenta, mammary gland,
ovary, skeletal muscle, stomach, pituitary gland, and lymphoid
tissue (Sainz et al., 2009; Park and Ahima, 2015). Binding of
leptin with its receptor (Ob-R) activates cytoplasmic tyrosine
kinases of the Janus kinase family (JAKs), which then activate
STAT proteins (Ceddia, 2005) (Figure 4). It has been reported
that muscle mass and fiber size are significantly lower in leptin
deficient ob/ob mice compared to wild type mice that were
administered leptin. This data indicates that decreased leptin is
associated with reduced skeletal muscle mass in leptin-deficient
ob/ob mice (Sainz et al., 2009). Leptin administration in 12
week old ob/obmice show upregulation of myocyte proliferation,
elevated myogenin and myonectin transcript levels in addition
to reduced mRNA expression of myostatin, dystrophin, MuRF1
and MAFbx (Rodriguez et al., 2015). Recombinant leptin bearing
mice show higher expression levels of MyoD and myogenin
compared to leptin receptor knockout mice. Myoblast formation
rates are also higher in these mice (Arounleut et al., 2013).
Both leptin and insulin resistance in myocytes are associated
with the onset of obesity, type 2 diabetes, and other metabolic
disorders (Yang et al., 2012). Combined, these side effects of
obesity dramatically impair muscle synthesis.
Effect of IL-6 on Muscle
High doses or chronic administration of IL-6 in rats ormice cause
increased degradation of proteins in skeletal muscle, although the
normal levels of IL-6 have been proven hypertrophic (Munoz-
Canoves et al., 2013; Pelosi et al., 2014). Insertion of the IL-6
gene into transgenic mice has been shown to elevate circulating
IL-6, which is associated with severe muscle atrophy by the age
of 10 weeks (Munoz-Canoves et al., 2013). Blockade of IL-6
signaling by the IL-6R antibody causes the regeneration ofmuscle
(Carson and Baltgalvis, 2010). Indirect effects of IL-6 on IGF-1
signaling have also been reported. Increased circulating levels of
IL-6 are associated with significantly reduced serum IGF-1 levels
and elevated expression of SOCS3 mRNA in muscle (Munoz-
Canoves et al., 2013; Pelosi et al., 2014), suggesting the role of IL-6
as a negative regulator of IGF-1 signaling. The entire mechanism
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FIGURE 4 | Possible antagonistic effects of obesity on myocyte signaling to accelerate muscle atrophy. (a) Anabolic pathways: IGF signaling is the main
anabolic signaling pathway in the myocyte. Binding of I/IGF with their receptor (IR) activates IR, which in turn activates AKT through successive activations of IRS,
PI3K and PDK1. Activated AKT, then in turn activates mTOR and NF-κB as well as inhibits FOXO and GSK3β. mTOR is a positive regulator of muscle because it
induces the synthesis of muscle proteins and inhibits proteolysis by activating S6 kinase beta-1 (S6K1), whereas both FOXO and GSK3β are negative regulators of
muscle because FOXO is a transcription factor that upregulates the transcription of E3 ubiquitin ligases and GSK3β inhibits both eIF2B and nebulin. Activated IR also
inhibits Csp3 functioning through inducing the activation of cellular inhibitor of apoptosis protein 1 (cIAP1) and MAPK/ERK kinase (MEK). Leptin signaling is another
anabolic signaling pathway that induces muscle protein synthesis through the JAK2/STAT signaling pathway induced by activated leptin receptor long isoform
(LEPRb). Activated JAK2 may induce I/IGF signaling via the activation of IRS. (b) Catabolic pathways: Binding of GC with GR in cytosol forms the GC-GR complex and
translocates into the nucleus where it induces the transcription of FOXO1, Atrogin-1, and MuRF-1 through binding with the respective genes. GC signaling also
induces the upregulation of Kruppel-like factor 15 (KLF15), regulated in development and DNA damage responses -1 (REDD1) and pyruvate dehydrogenase kinase 4
(PDK4). Both KLF15 and REDD1 inhibit protein synthesis in muscle by sequestering mTOR and by inducing FOXO activation (by KLF15). PDK4 reduces glucose
oxidation. IL-6 signals through the IL6R/JAK/STAT pathway and induces the overexpression of the suppressor of cytokine signaling-3 (SOCS3), a negative regulator of
muscle. Myostatin induced activated ActRIIB signals through the SMAD2/3 dependent pathway and induces the expression of some proteins which downregulate the
expression of MyoD and myogenin. Myostatin also induces the upregulation of atrogin1 and MuRF1 through the activation of FOXO. AGE induces the expression of
Csp3 through the RAGE/P38MAPK signaling pathway resulting in apoptosis of myocytes. The active receptor for advanced glycation end products (RAGE) also
induces the generation of ROS by activating the enzyme, NADPH oxidase. This ROS can induce the expression of Bnip3 through the activation of FOXO, and also
activates NFκB via the MAPK-JNK/p38/ERK1/2 signaling pathway. Ang II induced activation of ATR1 triggers the generation of ROS, which in turn upregulates the
expression of MuRF1 via IKK/NF-κB mediated signaling and also accelerates proteolysis via Csp3 activation. Ang II signaling downregulates IGF signaling by
suppressing IRS1 and also inhibits mitochondrial biogenesis. TNF-α induces the expression of iNOS, Murf1, and Atrogin1 through NF-κB and P38/MAPK mediated
signaling pathway. Active TNFR also inhibits IRS via JNK activation and ultimately downregulates IGF signaling. Sarcomeric protein derived AMP also activates AMPK,
that in turns activates FOXO, induces mitochondrial fatty acid (FA) oxidation to generate ROS and inhibits mTOR. PTEN acts as a negative regulator of I/IGF signaling
by sequestering IRS. (c) Obesity negatively regulates the anabolic pathways and positively regulates the catabolic pathways, ultimately causing muscle atrophy.
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by which IL-6 induces SOCS3 overexpression is still obscure,
but evidence supports the hypothesis that IL-6 exerts its effect
mainly through the JAK-STAT3 signaling pathway (Figure 4).
In accordance with this finding, infusion of IL-6 in skeletal
muscle induced STAT3 activation and overexpression of SOCS3
transcription, with a reduced number of myofibrillar proteins
(Munoz-Canoves et al., 2013). Recently, the expression levels of
IL-6 and its receptor, IL-6R, from lean, overweight and obese
individuals were examined and it was determined that expression
levels of IL-6 and IL-6R were elevated in obese individuals
compared to the lean and overweight groups (Sindhu et al., 2015).
A recent study showed that the overexpression of SOCS3 in
skeletal muscle interferes with calcineurin signaling leading to
defects in the sarcoplasmic reticulum and mitochondria. Obesity
is associated with overexpression of SOCS3 in human and rodent
skeletal muscle (Jorgensen et al., 2013). SOCS3 also exerts its
negative effect on muscle by sequestering leptin, leading to the
leptin resistance in skeletal muscle observed in obesity (Yang
et al., 2012; Jorgensen et al., 2013).
Effect of TNF-α on Muscle
It has been identified from several studies that elevated levels
of TNF-α are associated with increased muscle atrophy and
apoptosis (Gallo et al., 2015). Obesity and T2DM are associated
with a chronic inflammatory response that is characterized
by increased production of TNF-α and other proinflammatory
cytokines (Steinberg et al., 2006). TNF-α exerts its effects through
the NF-κB and P38/MAPK mediated signaling pathway and
stimulates the expression of iNOS, MuRF1 and MAFbx (Hall
et al., 2011; Fanzani et al., 2012; Wang et al., 2014) (Figure 4).
iNOS induces the production of nitric oxide (NO), which
inhibits MyoD (an important myogenic transcription factor)
via peroxynitrite (ONOO−) generation. iNOS also suppresses
muscle protein synthesis through oxidative modification of
JUN-D by inhibition of mTOR signaling and by increased
phosphorylation of eILF2α and eukaryotic elongation factor 2
(eEF2) (Hall et al., 2011). MuRF1 and MAFbx trigger muscle
protein degradation via UPS (Fanzani et al., 2012; Wang et al.,
2014). TNF-α may also act as a potential inhibitor of IGF-1/AKT
signaling by inhibiting the activation of IRS via JNK (Schiaffino
et al., 2013). High fat diet induced obesity is associated with
increased activation of JNK1 resulting in the development of
obesity-induced insulin resistance (Sabio et al., 2010). Obesity
is also associated with peripheral neuropathy mediated muscle
atrophy or direct induction of muscle atrophy through TNF-α
mediated pathways, thereby increasing muscle weakness (Sishi
et al., 2011; Van et al., 2011).
Effect of IL-10 on Muscle
A knockout study in mice has shown that endogenous IL-
10 attenuates IL-6 expression in skeletal muscle (Huey et al.,
2008). Inhibitory effects of IL-6 on insulin signaling in skeletal
muscles are reduced dramatically following treatment with IL-
10 (Kim et al., 2004), showing that IL-10 acts as a negative
regulator of IL-6. Reduced levels of circulating IL-10 are observed
in obese muscle causing lipid-induced insulin resistance. As
a result, after 3 weeks of high fat diet, mice with muscle-
specific overexpression of IL-10 develop obesity, but remain
insulin sensitive in skeletal muscle (Hong et al., 2009; Makki
et al., 2013). The insulin sensitizing and antidiabetic effects
of adiponectin are well-characterized (Liu and Sweeney, 2014).
Another study implied that disruption of muscle specific
AdipoR1 downregulates the adiponectin-mediated elevation of
intracellular Ca2+ concentration, and ultimately reduced the
formation of oxidative type I myofibers in skeletal muscle
through the inactivation of Ca2+/calmodulin-dependent protein
kinase (CAMK), AMP dependent protein kinase (AMPK) and
Sirtuin 1 (SIRT1) (Iwabu et al., 2010). In myocytes, binding
of adiponectin with its receptor (ADIPOR1/2) activates AMPK
signaling and enhances fatty acid oxidation and glucose uptake
in muscle (Kwon and Pessin, 2013). Obesity is characterized
by the decreased generation of adiponectin in skeletal muscle
and thereby, may have causal roles in mitochondrial dysfunction
and insulin resistance seen in diabetic models (Iwabu et al.,
2010; Makki et al., 2013). The effects of omentin on muscle cells
have not been identified yet, but several studies have reported
its anti-inflammatory roles in other types of cells. For example,
omentin-1 triggers AKT/PKB phosphorylation and thereafter
accelerates insulin induced glucose uptake in human visceral
and subcutaneous adipocytes. Additionally, omentin-1 inhibits
C-reactive protein (CRP) and TNF-α induced NF-κB activation
in human endothelial cells (Kwon and Pessin, 2013). Lower
expression levels of omentin in the serum of obese individuals
have been detected and are thought to be inversely related to
obesity (Duan et al., 2011; Kwon and Pessin, 2013). IFNγ/NF-κB
signaling pathway has been found to induce muscle atrophy in
patients affected with cancer or chronic inflammation (Di et al.,
2012). Elevated expression of IFN-γ and its receptor have been
observed in obese subjects with defective muscle growth (Khan
et al., 2014). All of these factors contribute to decreased muscle
mass.
Effect of Ectopic Lipid Accumulation on
Muscle
Obesity is characterized by ectopic lipid accumulation where
elevated lipid storage takes place in subcutaneous and visceral
adipose depots and non-adipose organs. There are two pools
of lipids in skeletal muscles: extramyocellular lipids (EMCL)
localized between muscle fibers and intramyocellular lipids
(IMCL) located within muscle cells. An adipose tissue rich
portion of EMCL which is closely associated with the muscle is
known as intermuscular adipose tissue (IMAT). Accumulation
of IMAT in obese individuals is positively correlated with
insulin resistance and reduced muscle performance (Akhmedov
and Berdeaux, 2013). Triacylglycerols (TAG), acyl CoAs,
diacylglycerols and ceramides which are the major constituents
of IMCL have been observed in higher levels in obese individuals
compared to nonobese ones (Akhmedov and Berdeaux, 2013;
Li et al., 2015). Lipotoxicity caused by accumulated acyl
CoAs, diacylglycerols and ceramides adversely affect muscle
development and regeneration (Akhmedov and Berdeaux,
2013). In obese rats and humans it was found that skeletal
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muscle triglycerides, diacylglycerols, and ceramides cause insulin
resistance during obesity through different signalingmechanisms
(Amati et al., 2011). Ceramides have also been recognized as
a potential suppressor of myogenin, a transcription factor for
myogenesis, as it suppresses the activity of myogenin through
inhibition of phospholipase D (PLD) (Jadhav et al., 2013;
Babenko and Kharchenko, 2015).
Effect of Extracellular Glucose and AGE on
Muscle
Obesity is associated with an elevated level of extracellular
glucose in the body caused by IR and this glucose is a
potential precursor of AGE formation (Unoki et al., 2010;
Andrade et al., 2015). Binding of AGE with its receptor,
RAGE, induces the formation of ROS via the NADPH mediated
signaling pathway (Daffu et al., 2013) (Figure 4). AGE is
also associated with apoptosis of smooth muscle cells through
expression of Csp3 via p38-MAPK dependent pathway (Wang
et al., 2015). Overproduction of ROS causes the activation of
FOXO3, a transcription factor that induces the expression of
Bcl-2/adenovirus E1B 19kD-interacting protein 3 (Bnip3), which
causes protein degradation, and also acts as an inhibitor of
mTOR (Frost and Lang, 2011). Elevated levels of ROSmay trigger
muscle atrophy through three different signaling pathways: (1)
the Ca2+ dependent calpain signaling pathway, (2) the MAPK-
JNK/p38/ERK1/2 signaling pathway, and (3) the NF-κB signaling
pathway (Fanzani et al., 2012).
Effect of Glucocorticoids on Muscle
Several studies have reported the role of GCs in muscle
atrophy. However, in 2013, Schakman et al. elucidated the
effects of GCs on muscle atrophy by illustrating decreased
fiber cross-sectional areas and reduced myofibrillar protein
content. GC-induced muscle atrophy results from increased
muscle proteolysis through the activation of UPS and lysosomal
systems. The effect of GC on these two proteolytic systems
is mediated through the upregulation of several atrogenes like
FOXO, Atrogin-1, and MuRF-1 (Bonaldo and Sandri, 2013;
Schakman et al., 2013; Schiaffino et al., 2013; Patel et al., 2014).
GCs exert their inhibitory effects on muscle protein synthesis
mainly through inhibition of the mTOR/S6 kinase 1 pathway
(Schakman et al., 2013; Patel et al., 2014). REDD1 and KLF15
are two potential inhibitors of mTOR and it has been concluded
that GCs induce the expression of REDD1 and KLF15 genes in
skeletal muscle during atrophy (Im et al., 2007; Shimizu et al.,
2011). Overexpression of REDD1 and KLF15 in skeletal muscle
has been implicated during obesity (Im et al., 2007; Williamson
et al., 2014). Myostatin is a negative regulator of muscle because
it inhibits muscle cell proliferation and protein synthesis. It has
been reported that GC treatment increases the expression of
myostatin in myocytes (Patel et al., 2014). GCs further decrease
glucose utilization by up regulating PDK4 expression in skeletal
muscle (Figure 4), by binding with the glucocorticoid response
element (GRE) since PDK4 is a suppressor of glucose oxidation
(Jeong et al., 2012). Overexpression of PDK4 mRNA has been
found in cultured myotubes from obese and type 2 diabetic
patients (McAinch et al., 2015). The use of steroid hormone
treatments in the development of different types of metabolic
disorders is well-established, and the chronic use of steroid
hormones, such as glucocorticoids, may trigger the development
of obesity accompanied with rapid muscle atrophy (Lee et al.,
2014; Patel et al., 2014).
FIGURE 5 | Possible pathways of obesity-induced osteoporosis and bone fractures.
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Effect of Angiotensin II on Muscle
Ang II has been identified as antagonistic to insulin action
because several lines of evidence have proven that Ang II inhibits
insulin-induced tyrosine phosphorylation of IRS1, activation
of AKT, and GLUT4 translocation to the plasma membrane.
These actions can be reversed by pretreating myotubes with
losartan (blocker of AT1 and AT2 receptor) or apocynin (a
NADPH oxidase inhibitor) (Wei et al., 2006). Ang II treated
C2C12 cells showed reduced expression of the genes involved
in mitochondrial biogenesis and also Ang II functionality was
inhibited by the blockade of the AT2 receptor (AT2R) (Mitsuishi
et al., 2009). These results suggest an important role of Ang II
in the inhibition of insulin signaling as well as downregulation
of mitochondrial biogenesis in skeletal muscle through NADPH
oxidase activation and ROS generation (Wei et al., 2006;
Mitsuishi et al., 2009). Binding of Ang II with its receptor, ATR1,
induces NADPH oxidase mediated generation of ROS, which
in turn induces the upregulation of MuRF1 through the NF-
κB signaling pathway as well as activation of Csp3, ultimately
accelerating protein degradation. Ang II is also reported to
induce the expression of Myostatin, GC, TNF-α and IL-6 in
muscle and thereby induces muscle atrophy (Yoshida et al.,
2013). In 2014, however, Oliveira et al. found that inhibition of
AT1R with an AT1 receptor blocker prevented IR in rats with
diet-induced obesity (Oliveira-Junior et al., 2014).
Effect of Growth Hormone on Muscle
Use of GH has been identified to improve physical fitness
through accelerating collagen synthesis in the tendon and skeletal
muscle that leads to better performance in exercise and increased
muscle strength (Tavares et al., 2013). Obesity is associated with
reduced levels of GH in the muscle and liver (Clasen et al.,
2014). Deficiency of GH causes the reduction of muscle mass
and strength and these can be reversed successfully by the
supplementation of GH (Weber, 2002). GH triggers the higher
expression of IGF-1 primarily of hepatic origin, although it also
induces synthesis of IGF-1 in most non-hepatic tissues. A recent
study showed that GH triggers STAT5b phosphorylation in
muscle and fat in obese subjects along with increased expression
of CISH and SOCS2, two potential cytokine inhibitors (Velloso,
2008).
Effect of Testosterone and Estrogen on
Muscle
Testosterone and estrogen have been characterized as positive
regulators of skeletal muscle mass in adult males and females
respectively (Enns and Tiidus, 2010; Kovacheva et al., 2010).
Testosterone exerts its effects by suppressing oxidative stress
and myostatin levels, and activation of JNK and the cyclin-
dependent kinase inhibitor p21 (Enns and Tiidus, 2010). During
obesity, both testosterone and estrogen hormone levels decrease
significantly in older males and females, respectively (Freeman
et al., 2010; Wang et al., 2011). It is well-established that
reduced levels of vitaminD are frequently associated with inferior
physical performance and increased risk of falls due to impaired
muscle activities. Depletion of vitamin D levels is a hallmark of
obesity-induced muscle atrophy (Cipriani et al., 2014).
CONCLUSION
To date, obesity has not been identified as an exact cause of
osteoporosis, but it is plausible from this review to conclude that
obesity may be a cause of osteoporosis and bone fractures due
to its diverse range of effects on different systems of the human
body. Obesity primarily regulates the skeletal system (specifically
osteoblast, osteocyte, osteoclast and bone microcirculation) and
the muscular system (mainly myocyte) resulting in osteoporosis
as well as increased bone fractures due to decreased muscle
strength (Lampropoulos et al., 2012) (Figure 5). Obesity is
associated with increased expression of PTH, duodenal 5-HT, IL-
6, AGEs and THF-α, as well as decreased expression of BMP,
IGF, Activin/TGF-β, Wnt, brain 5-HT, estrogen and EPCs. All of
these factors negatively regulate the differentiation, proliferation,
survival and functioning of osteoblasts and thereby cause
osteoporosis and bone fractures via reduced bone formation
followed by low bone quality (Cao, 2011). Obesity is associated
with exogenous GC induced apoptosis of osteocytes which result
in decreased bone density followed by low bone quality, and
ultimately, osteoporosis (Lee et al., 2014; Moutsatsou et al.,
2012). Obesity induces the MSCs to generate more and more
adipocytes rather than osteoblasts, and thereby increase bone
marrow cavities followed by increases in bone fragility and
decreased bone microcirculation (Cao, 2011). Obesity positively
regulates osteoclasts functioning by upregulating the synthesis
of RANKL, TNF-α, MCP1, IL-6, PTH and M-CSF while
also downregulating ERα expression, thereby accelerating bone
resorption. Obesity-induced increases in body weight escalate
the chance of bone fractures by increasing the risk of fall
(Valerio et al., 2012). Skeletal muscle activities are inversely
related to obesity because obesity accelerates muscle atrophy and
decelerates muscle strength via regulating the activities of TNF-α,
Ang II, AGEs, Myostatin, exogenous GC, IL-6, I/IGF, vitamin D,
Ca2+, estrogen, testosterone and leptin. Skeletal muscle atrophy
decreasesmuscle strength leading to the increased risk of falls and
ultimately increased chance of bone fractures.
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